HK1180337A1 - Compounds useful in the modulation of blood uric acid levels - Google Patents

Compounds useful in the modulation of blood uric acid levels

Info

Publication number
HK1180337A1
HK1180337A1 HK13107698.5A HK13107698A HK1180337A1 HK 1180337 A1 HK1180337 A1 HK 1180337A1 HK 13107698 A HK13107698 A HK 13107698A HK 1180337 A1 HK1180337 A1 HK 1180337A1
Authority
HK
Hong Kong
Prior art keywords
modulation
uric acid
compounds useful
acid levels
blood uric
Prior art date
Application number
HK13107698.5A
Other languages
English (en)
Chinese (zh)
Inventor
巴里．
．夸爾特
讓-吕克．吉拉爾代
埃斯米爾．古尼奇
利-泰恩．葉
Original Assignee
亞德生化公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1180337(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 亞德生化公司 filed Critical 亞德生化公司
Publication of HK1180337A1 publication Critical patent/HK1180337A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK13107698.5A 2007-11-27 2011-01-31 Compounds useful in the modulation of blood uric acid levels HK1180337A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99057407P 2007-11-27 2007-11-27
US9438808P 2008-09-04 2008-09-04

Publications (1)

Publication Number Publication Date
HK1180337A1 true HK1180337A1 (en) 2013-10-18

Family

ID=40679222

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13107698.5A HK1180337A1 (en) 2007-11-27 2011-01-31 Compounds useful in the modulation of blood uric acid levels
HK12113097.1A HK1172326A1 (en) 2007-11-27 2011-01-31 Compounds and compositions and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12113097.1A HK1172326A1 (en) 2007-11-27 2011-01-31 Compounds and compositions and methods of use

Country Status (36)

Country Link
US (8) US8084483B2 (fi)
EP (2) EP2217577B1 (fi)
JP (3) JP5099794B2 (fi)
KR (2) KR101291643B1 (fi)
CN (3) CN102643241B (fi)
AR (1) AR069753A1 (fi)
AU (2) AU2008329673C1 (fi)
BR (1) BRPI0819847B1 (fi)
CA (1) CA2706858C (fi)
CL (1) CL2008003529A1 (fi)
CY (1) CY2019010I1 (fi)
DK (1) DK2217577T3 (fi)
EA (2) EA201270666A1 (fi)
EC (1) ECSP10010310A (fi)
ES (1) ES2513390T3 (fi)
HK (2) HK1180337A1 (fi)
HR (1) HRP20140950T1 (fi)
HU (1) HUS1900009I1 (fi)
IL (1) IL205974A (fi)
LT (1) LTPA2019003I1 (fi)
LU (1) LUC00103I2 (fi)
MA (1) MA31936B1 (fi)
ME (2) ME01294B (fi)
MX (1) MX2010005776A (fi)
MY (1) MY147370A (fi)
NO (1) NO2016016I2 (fi)
NZ (4) NZ585583A (fi)
PL (1) PL2217577T3 (fi)
PT (1) PT2217577E (fi)
RS (1) RS53569B1 (fi)
SG (1) SG183721A1 (fi)
SI (1) SI2217577T1 (fi)
TN (1) TN2010000237A1 (fi)
TW (1) TWI415840B (fi)
WO (1) WO2009070740A2 (fi)
ZA (1) ZA201003769B (fi)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101083987B (zh) * 2004-08-25 2011-01-26 阿迪亚生命科学公司 作为HIV逆转录酶抑制剂的S-三唑基α-巯基乙酰苯胺
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
PL2217577T3 (pl) * 2007-11-27 2015-01-30 Ardea Biosciences Inc Nowe związki, kompozycje i sposoby stosowania
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
JP2012502050A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
CA2741368A1 (en) * 2008-10-24 2010-04-29 Barry D. Quart Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio) acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010135536A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
JP2012527475A (ja) * 2009-05-20 2012-11-08 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及び方法
NZ600984A (en) * 2010-01-08 2013-10-25 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
US9402827B2 (en) * 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (es) 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
EP2582664A4 (en) 2010-06-16 2014-07-09 Ardea Biosciences Inc PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CN103249417A (zh) * 2010-10-15 2013-08-14 阿迪亚生命科学公司 用于治疗高尿酸血症及相关疾病的方法
AU2011322099A1 (en) * 2010-10-28 2013-05-02 Mapi Pharma Limited Polymorphs of febuxostat
ES2614914T3 (es) * 2010-12-30 2017-06-02 Ardea Biosciences, Inc. Formas polimórficas de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acético y usos de las mismas
WO2012122532A2 (en) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions and methods for treatment of hyperuricemia
RS56225B1 (sr) * 2011-05-24 2017-11-30 Ardea Biosciences Inc Hipertenzija i hiperurikemija
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2704233T3 (es) 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
DK2775836T3 (en) * 2011-11-04 2018-12-03 Cymabay Therapeutics Inc PROCEDURES FOR TREATING GIG RETURN
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
MX354846B (es) * 2011-11-04 2018-03-22 Cymabay Therapeutics Inc Metodos para tratar gota en sub-poblaciones de pacientes.
AR089812A1 (es) * 2012-01-27 2014-09-17 Teijin Pharma Ltd Agente terapeutico para la diabetes mellitus
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US9637469B2 (en) * 2012-11-14 2017-05-02 Teijin Pharma Limited Pyridine derivative
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
PL2998296T3 (pl) 2013-05-13 2018-12-31 Shanghai Hengrui Pharmaceutical Co. Ltd. Pochodna kwasu cykloalkilowego, sposób jej otrzymywania i jej zastosowanie farmaceutyczne
WO2014198241A1 (en) * 2013-06-14 2014-12-18 Sunshine Lake Pharma Co., Ltd. Thio-1,2,4-triazole derivatives and method for preparing the same
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN104447589B (zh) * 2013-11-20 2017-01-11 广东东阳光药业有限公司 一种尿酸调节剂的制备方法及其中间体
WO2015075561A2 (en) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103588716A (zh) * 2013-11-22 2014-02-19 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法
US9969701B2 (en) * 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
CN105294585B (zh) * 2014-07-02 2019-02-12 成都海创药业有限公司 一种治疗痛风的化合物
CN106036135A (zh) * 2014-07-25 2016-10-26 许伟琦 一种防止结石、快速排结石的药物、组合物、兽药
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341365A (zh) * 2014-10-27 2015-02-11 张远强 卤代三氮唑丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326994A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326995A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326996A (zh) * 2014-10-27 2015-02-04 张远强 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途
CN104341364A (zh) * 2014-10-27 2015-02-11 张远强 三氮唑丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104529848A (zh) * 2014-11-10 2015-04-22 安徽万邦医药科技有限公司 一种1-环丙基-4-异硫氰酰基萘的合成方法
AU2015371308A1 (en) 2014-12-23 2017-08-03 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
CN107108478B (zh) * 2014-12-29 2020-04-24 日本化学药品株式会社 Urat1抑制剂
CN105985295B (zh) * 2015-02-17 2018-11-20 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物
CN105622531A (zh) * 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
CN104710374A (zh) * 2015-04-14 2015-06-17 安徽省逸欣铭医药科技有限公司 一种痛风新化合物及制备方法、用途及其药物制剂
CN106187926B (zh) * 2015-04-30 2018-11-27 天津药物研究院有限公司 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
BR112018002648B1 (pt) * 2015-08-26 2024-01-09 Stagen Co., Ltd Intensificador da atp intracelular humana ou animal
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105301126B (zh) * 2015-10-10 2021-02-12 大道隆达（北京）医药科技发展有限公司 一种托匹司他有关物质的分析方法
WO2017091513A1 (en) * 2015-11-24 2017-06-01 Daiichi Sankyo Company, Limited Novel azole derivatives as apelin receptor agonist
CA3018115A1 (en) 2015-12-28 2017-07-06 Shanghai Fochon Pharmaceutical Co., Ltd. Indolizine derivatives, composition and methods of use
US20170319552A1 (en) * 2016-02-24 2017-11-09 Ardea Biosciences, Inc. Atropisomers of triazole derivative
CN107176930B (zh) * 2016-03-11 2020-12-01 广东赛烽医药科技有限公司 2-[5-溴-4-(4-氟代环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基]乙酸化合物及其应用
CN107337649B (zh) * 2016-04-29 2020-10-16 四川科伦药物研究院有限公司 一种乙酸钠水合物无定型及其制备方法和用途
US10829483B2 (en) 2016-05-23 2020-11-10 Cstone Pharmaceutical (Suzhou) Co., Ltd. Thiophene, manufacturing method thereof, and pharmaceutical application of same
CN106074540B (zh) * 2016-06-10 2018-10-16 江西博屾医疗器械有限公司 一种用于高尿酸血症治疗的药物组合物及其应用
CN105943552A (zh) * 2016-06-17 2016-09-21 王枝宝 一种氢氧化钾的医药用途
JP7050009B2 (ja) * 2016-06-17 2022-04-07 メッドシャイン ディスカバリー インコーポレイテッド ハロゲン化合物およびその軸性キラリティ異性体
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
CZ2016611A3 (cs) * 2016-09-30 2018-05-09 Zentiva, K.S. Způsob výroby 2-(5-brom-4-(1-cyklopropylnaftalen-4-yl)-4H-1,2,4-triazol-3-ylthio)octové kyseliny - lesinuradu
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
CA3042738A1 (en) 2016-11-10 2018-05-17 Apotex Inc. Novel crystalline forms of lesinurad
JP7406990B2 (ja) 2016-11-11 2023-12-28 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト血漿様培地
CN108164471B (zh) * 2016-12-07 2019-09-13 浙江京新药业股份有限公司 Lesinurad衍生物及其制备方法和用途
US10351537B2 (en) 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (zh) * 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
EP3712148B1 (en) 2017-11-23 2021-07-07 Medshine Discovery Inc. Crystal forms of a urat1 inhibitor, and preparation methods therefor
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
EP3725781B1 (en) * 2017-12-15 2022-11-30 Medshine Discovery Inc. Crystal and salt of 4-(naphthalen-1-yl)-4h-1,2,4-triazole compound and preparation method therefor
CN109369783B (zh) * 2018-11-30 2021-09-10 昆明医科大学 一种多肽rdp1及其提纯方法与应用
CN111320588B (zh) * 2018-12-14 2024-02-09 上海奥博生物医药股份有限公司 一种纯化Lesinurad的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006101A (en) 1932-07-05 1935-06-25 Meaf Mach En Apparaten Fab Nv Reversing mechanism for dry gas meters
US4198513A (en) * 1970-09-25 1980-04-15 Merck & Co., Inc. 1,2,4-Triazoles
NL7112373A (fi) * 1970-09-25 1972-03-28
JPS5641637B2 (fi) 1973-11-26 1981-09-29
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US6832996B2 (en) 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
CA2251368A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
WO2000027850A2 (en) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
US6414147B1 (en) 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
US6593077B2 (en) 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
EP1363877A2 (en) 2001-03-02 2003-11-26 SmithKline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
PT1471065E (pt) 2002-01-28 2008-03-13 Fuji Yakuhin Co Ltd Novos compostos de 1,2,4-triazole
JP2005529923A (ja) 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物
EA009478B1 (ru) * 2002-08-23 2008-02-28 Ардеа Байосайенсиз, Инк. Ненуклеозидные ингибиторы обратной транскриптазы
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
MXPA05008364A (es) 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevencion de una infeccion por vih.
AU2004274185B2 (en) 2003-09-25 2009-12-10 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2005046724A1 (ja) 2003-11-14 2005-05-26 Human Cell Systems, Inc. 血管障害や高血圧症の治療・予防剤、及びそのスクリーニング方法
JP2007515429A (ja) 2003-12-19 2007-06-14 エリクシアー ファーマシューティカルズ， インコーポレイテッド 障害を治療する方法
CA2558224A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
CN1934095A (zh) * 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
BRPI0511510A (pt) * 2004-05-25 2007-12-26 Metabolex Inc composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo
US20060013556A1 (en) 2004-07-01 2006-01-19 Thomas Poslinski Commercial information and guide
CN101083987B (zh) 2004-08-25 2011-01-26 阿迪亚生命科学公司 作为HIV逆转录酶抑制剂的S-三唑基α-巯基乙酰苯胺
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
JPWO2007043401A1 (ja) * 2005-10-07 2009-04-16 キッセイ薬品工業株式会社 含窒素複素環化合物およびそれを含有する医薬組成物
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
CA2653336C (en) 2006-05-25 2014-10-28 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
JP2010516691A (ja) 2007-01-19 2010-05-20 タケダ ファーマシーティカルズ ノース アメリカ，アイエヌシー． 抗炎症剤及びキサンチン酸化還元酵素阻害剤を用いて痛風の突発を抑え、又はその数を減少させる方法
PL2217577T3 (pl) * 2007-11-27 2015-01-30 Ardea Biosciences Inc Nowe związki, kompozycje i sposoby stosowania
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
RS56225B1 (sr) 2011-05-24 2017-11-30 Ardea Biosciences Inc Hipertenzija i hiperurikemija

Also Published As

Publication number Publication date
US20160221970A1 (en) 2016-08-04
SI2217577T1 (sl) 2014-11-28
ME01996B (me) 2015-05-20
US8283369B2 (en) 2012-10-09
CN102643241B (zh) 2015-01-21
KR101411806B1 (ko) 2014-06-24
US20110268801A1 (en) 2011-11-03
AU2012203172A1 (en) 2012-06-21
EP2217577B1 (en) 2014-08-06
CY2019010I2 (el) 2019-11-27
US8084483B2 (en) 2011-12-27
US20110293719A1 (en) 2011-12-01
US8546437B2 (en) 2013-10-01
MY147370A (en) 2012-11-30
KR101291643B1 (ko) 2013-08-01
EA201270666A1 (ru) 2012-12-28
MA31936B1 (fr) 2010-12-01
LUC00103I2 (fi) 2019-12-27
RS53569B1 (en) 2015-02-27
US20190142805A1 (en) 2019-05-16
US10183012B2 (en) 2019-01-22
WO2009070740A3 (en) 2009-08-13
JP5905934B2 (ja) 2016-04-20
DK2217577T3 (da) 2014-10-20
CN102643241A (zh) 2012-08-22
EA201000897A1 (ru) 2010-12-30
AR069753A1 (es) 2010-02-17
HUS1900009I1 (hu) 2019-03-28
CN103058944A (zh) 2013-04-24
CY2019010I1 (el) 2019-11-27
PT2217577E (pt) 2014-10-20
KR20100085195A (ko) 2010-07-28
CA2706858A1 (en) 2009-06-04
TW200927733A (en) 2009-07-01
NZ595035A (en) 2012-11-30
CN101918377A (zh) 2010-12-15
JP5099794B2 (ja) 2012-12-19
MX2010005776A (es) 2010-08-31
AU2008329673A1 (en) 2009-06-04
NO2016016I1 (no) 2016-08-17
US20090197825A1 (en) 2009-08-06
US20120164222A1 (en) 2012-06-28
ES2513390T3 (es) 2014-10-27
NO2016016I2 (no) 2016-08-17
ME01294B (me) 2013-06-20
AU2008329673C1 (en) 2012-10-25
NZ601774A (en) 2013-07-26
BRPI0819847B1 (pt) 2022-01-11
EP2217577A4 (en) 2010-12-08
SG183721A1 (en) 2012-09-27
JP2012184234A (ja) 2012-09-27
LTPA2019003I1 (lt) 2019-02-25
KR20120084787A (ko) 2012-07-30
TWI415840B (zh) 2013-11-21
HRP20140950T1 (hr) 2014-12-05
TN2010000237A1 (en) 2011-11-11
ZA201003769B (en) 2011-02-23
EA018193B3 (ru) 2014-07-30
JP2014196373A (ja) 2014-10-16
AU2008329673B2 (en) 2012-04-12
EA018193B1 (ru) 2013-06-28
NZ601786A (en) 2014-02-28
EP2842948A1 (en) 2015-03-04
HK1172326A1 (en) 2013-04-19
EP2217577A2 (en) 2010-08-18
IL205974A (en) 2015-03-31
JP2011504935A (ja) 2011-02-17
US20170281601A1 (en) 2017-10-05
CA2706858C (en) 2013-12-24
LUC00103I1 (fi) 2019-02-19
US20140005136A1 (en) 2014-01-02
CL2008003529A1 (es) 2009-11-27
WO2009070740A2 (en) 2009-06-04
US8357713B2 (en) 2013-01-22
IL205974A0 (en) 2010-11-30
PL2217577T3 (pl) 2015-01-30
ECSP10010310A (es) 2010-07-30
CN103058944B (zh) 2015-08-05
NZ585583A (en) 2011-09-30
AU2012203172B2 (en) 2013-10-10
BRPI0819847A2 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
HK1180337A1 (en) Compounds useful in the modulation of blood uric acid levels
IL247136B (en) Compounds for reducing uric acid and their uses
ZA201204031B (en) Compounds, compositions and methods of using same for modulating uric acid levels
HK1155481A1 (en) Lactic acid bacterium having effect of lowering blood uric acid level
HK1152547A1 (en) Lactic acid bacteria having action of lowering blood uric acid level
EP2432774A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2191856A4 (en) BLOOD CLEANER
EP2265709A4 (en) MICRO-ORGANISMS FOR THE PREPARATION OF ADIPINIC ACID AND OTHER COMPOUNDS
EP2046353A4 (en) TREATMENT OF CANCER BY MODULATION OF PROTEIN KINASE, BASED ON ISO-ALPHA TETRAHYDRO ACIDS
EP2129369A4 (en) TREATMENT OF ADHD
HK1148435A1 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2010135536A9 (en) Methods of modulating uric acid levels
EP2180787A4 (en) MODULATION OF TYPE II DIABETES BY NITRATED FATTY ACIDS
HK1177228A1 (en) Lactic acid bacteria having action of lowering blood uric acid level
PL2211874T3 (pl) Sterylizowane roztwory dializacyjne zawierające pirofosforan
HK1142928A1 (zh) 在經修飾的隨機寡核苷酸的存在下的核酸擴增
HK1146392A1 (en) Blood storage vessel
HK1143756A1 (en) Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
GB0822486D0 (en) Compounds for use in the treatment of pain
GB2460009A8 (en) Compounds and methods for the modulation of beta-1integrin function to mediate tissue repair
EP2311340A4 (en) MEDICAL SHOES
HK1146393A1 (en) Blood storage vessel
EP2157089A4 (en) THERAPEUTIC USES OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES
SG10201405790UA (en) Composition for lowering blood uric acid level
EP1944055A4 (en) FLAP CATHETER WITH FLAP